Vir Biotechnology向Norgine授予慢性乙型肝炎德尔塔治疗候选药物在欧洲、澳大利亚和新西兰的独家商业许可,并达成全球成本分担协议以支持持续的Eclipse临床开发计划。
Vir Biotechnology向Norgine授予慢性乙型肝炎德尔塔治疗候选药物在欧洲、澳大利亚和新西兰的独家商业许可,并达成全球成本分担协议以支持持续的Eclipse临床开发计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.